A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors

Trial Profile

A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs TP 0903 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Tolero Pharmaceuticals
  • Most Recent Events

    • 26 Jan 2017 This trial was being conducted by Tolero Pharmaceuticals. The Company has now been acquired by Sumitomo Dainippon Pharma, according to a Sumitomo Dainippon Pharma media release.
    • 02 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 12 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top